The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Porembskaya O.Ya.

Federal state budgetary institution «Research Institute of Experimental Medicine», North-West Division of Russian Academy of Medical Sciences, St. Petersburg

Kosenko I.M.

Department of Pharmacology with the course of clinical pharmacology and pharmacoeconomics, Sankt-Peterburg State Pediatric Medical University, Sankt-Peterburg, Russia

Pharmacotherapy of Chronic Venous Disease – how to choose Appropriate Venoactive Drug?

Authors:

Porembskaya O.Ya., Kosenko I.M.

More about the authors

Journal: Journal of Venous Disorders. 2018;12(3): 123‑133

DOI: 10.17116/flebo2018123123

Read: 7072 times

Contact the author
Table of contents

PHARMACOTHERAPY OF CHRONIC VENOUS DISEASE – HOW TO CHOOSE APPROPRIATE VENOACTIVE DRUG?
PHARMACOTHERAPY OF CHRONIC VENOUS DISEASE – HOW TO CHOOSE APPROPRIATE VENOACTIVE DRUG?

To cite this article:

Porembskaya OYa, Kosenko IM. Pharmacotherapy of Chronic Venous Disease – how to choose Appropriate Venoactive Drug? Journal of Venous Disorders. 2018;12(3):123‑133. (In Russ.)
https://doi.org/10.17116/flebo2018123123

Подписка 2026 Флебология (Journal of Venous Disorders)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Onset, Time Course and Dura­tion of Venoactive Drugs Effect on Venous Symptoms in Patients with Chro­nic Venous Disease. Journal of Venous Diso­rders. 2025;(3):206-215
Predictors of Venous Symptoms Improvement in Chro­nic Venous Disease Patients on Compression Therapy. Journal of Venous Diso­rders. 2025;(4):250-256
A Topi­cal Agent Based on Reco­mbinant Human Epidermal Growth Factor and Silver Sulfadiazine Acce­lerates the Healing of Venous (Chronic) Ulcers: A Prospective Comparative Non-Randomized Study ESKIZ. Journal of Venous Diso­rders. 2025;(4):284-294
Diosmin and Other Venoactive Drugs: Mechanisms of Action, Current and Future Indi­cations for Use. Journal of Venous Diso­rders. 2025;(4):307-314
Groin Soft Tissue Leiomyosarcoma or Femo­ral Vein Leiomyosarcoma?. Journal of Venous Diso­rders. 2025;(4):316-319
Effe­ctiveness of 600 mg Diosmin in Patients with Venous Edema and Symptoms in Real Life Practice. Journal of Venous Diso­rders. 2026;(1):50-56
Effi­cacy and Safety of Regu­latory Vascular Poly­peptides in Chro­nic Venous Diseases of the Lower Extremities: Resu­lts of a Randomized Placebo-Controlled Study. Journal of Venous Diso­rders. 2026;(2):89-96
Pharmacological support stra­tegies following endo­venous laser abla­tion in patients with vari­cose veins. Piro­gov Russian Journal of Surgery. 2025;(12):119-130
Vessel Due F Improves Treatment Outcomes in Vari­cose Veins in Patients with CEAP C4—C6. Russian Journal of Cardiology and Cardiovascular Surgery. 2026;(2):65-74
Abstract:

Chronic venous disease (CVD) is a multicomponent process that develops with time as a consequence of hemodynamic changes of macro- and microcirculation. The shear stress shift leads to leukocytes and macrophages activation and proinflammatory mediators (including ICAM-1, VEGF, MMP) secretion and smooth muscle cells switching to the secretory type. The cascade of the inflammatory reactions causes venous wall remodeling, increasing the wall permeability and protein and fluid extravasation. Proinflammatory mediators activate nociceptors between endothelial and muscle cells. All those processes result in venous symptoms developing such as venous pain, oedema, legs heaviness and others well-known symptoms. Contemporary conceptions of chronic venous disease progression pathophysiological mechanisms allow us to determine possible effective therapeutic targets to reduce the degree of symptoms and signs manifestation. Venoactive drugs that nowadays are widely spread on the pharmaceutical market demonstrate varied effectiveness against different symptoms. Results of multipal investigations including metanalyses help us to define grades of recommendations for every venoactive drug and to individualize the treatment of patients according to the types of symptoms. Modern modifications of topical drugs with the help of adding essential phospholipids acting like transdermal delivery system enhance the effectiveness and help to reduce the severity of clinical manifistations of CVD especially in combination with venoactive drugs.

Keywords:

chronic venous disease
venoactive drugs
diosmin
micronized flavonoid fraction

Authors:

Porembskaya O.Ya.

Federal state budgetary institution «Research Institute of Experimental Medicine», North-West Division of Russian Academy of Medical Sciences, St. Petersburg

Kosenko I.M.

Department of Pharmacology with the course of clinical pharmacology and pharmacoeconomics, Sankt-Peterburg State Pediatric Medical University, Sankt-Peterburg, Russia

Close metadata

References:

  1. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu khronicheskikh zabolevanii ven. Flebologiya. 2013;7(2):1-47. (In Russ.)
  2. Boitsov SA, Samorodskaya IV. Mortality and lost years of life as a result of cardiovascular permature deaths. Kardiovaskulyarnaya terapiya i profilaktika. 2014;13(2):4-11. (In Russ.)
  3. Pokrovskii AV, Gradusov EG, Ignat’ev IM, Bredikhin RA. Diagnostika i lechenie varikoznoi bolezni. M.: RMAPO. 2013;80. (In Russ.)
  4. Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, Kirienko AI. Prevalence and risk factors for chronic enous disease in the General Russian Population. 2017;54(6):752-758. https://doi.org/10.1016/j.ejvs.2017.08.033
  5. Evans C, Fowkes F, Ruckley C, Lee A. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. Journal of Epidemiology & Community Health. 1999;53(3):149-153. https://doi.org/10.1136/jech.53.3.149
  6. Labropoulos N, Leon L, Kwon S, Tassiopoulos A, Gonzalez-Fajardo JA, Kang SS, Mansour MA, Littooy FN. Study of the venous reflux progression. J Vasc Surg. 2005;41(2):291-295. https://doi.org/10.1016/j.jvs.2004.11.014
  7. Kirienko AI, Zolotukhin IA, Yumin SM, Seliverstov EI. Lower limb varicose disease in men and women: findings of prospective study SPECTRUM. Angiol Sosud Khir. 2012;18(3):64-68. (In Russ.)
  8. Shevchenko YuL, Stoiko Yu.M. Osnovy klinicheskoi flebologii. Shiko. 2013;312. (In Russ.)
  9. Gohel M, Davies A. Pharmacological treatment in patients with C4, C5 and C6 venous disease. Phlebology: The Journal of Venous Disease. 2010;25(suppl 1): 35-41. https://doi.org/10.1258/phleb.2010.010s06
  10. Askerkhanov RP. Problems of etiology and pethogenesis of varicose veins of the lower extremities. Flebologiya. 2010;4(4):45-47. (In Russ.)
  11. Bergan J. Molecular mechanisms in chronic venous insufficiency. Ann Vasc Surg. 2007;21(3):260-266. https://doi.org/10.1016/j.avsg.2007.03.011
  12. Fitts M, Pike D, Anderson K, Shiu Y. Hemodynamic shear stress and endothelial dysfunction in hemodialysis access. Open Urol Nephrol J. 2014;7(1):33-44. https://doi.org/10.2174/1874303x01407010033
  13. Anwar M, Shalhoub J, Lim C, Gohel M, Davies A. The effect of pressure-induced mechanical stretch on vascular wall differential gene expression. J Vasc Res. 2012;49(6):463-478. https://doi.org/10.1159/000339151
  14. Bergan J, Pascarella L, Schmid-Schönbein G. Pathogenesis of primary chronic venous disease: insights from animal models of venous hypertension. J Vasc Surg. 2008;47(1):183-192. https://doi.org/10.1016/j.jvs.2007.09.028
  15. Takase S, Lerond L, Bergan J, Schmid-Schönbein G. The inflammatory reaction during venous hypertension in the rat. Microcirculation. 2000;7(1):41-52. https://doi.org/10.1111/j.1549-8719.2000.tb00741.x
  16. Lurie F, Kistner R, Eklof B, Kessler D. Mechanism of venous valve closure and role of the valve in circulation: a new concept. J Vasc Surg. 2003;38(5):955-961. https://doi.org/10.1016/s0741-5214(03)00711-0
  17. Lim C, Davies A. Pathogenesis of primary varicose veins. British Journal of Surgery. 2009;96(11):1231-1242. https://doi.org/10.1002/bjs.6798
  18. Ojdana D, Safiejko K, Lipska A, Sacha P, Wieczorek P, Radziwon P, Dadan J, Tryniszewska E. The inflammatory reaction during chronic venous disease of lower limbs. Folia Histochem Cytobiol. 2009;47(2). https://doi.org/10.2478/v10042-009-0029-8
  19. Caggiati A, Phillips M, Lametschwandtner A, Allegra C. Valves in small veins and venules. European Journal of Vascular and Endovascular Surgery. 2006;32(4):447-452. https://doi.org/10.1016/j.ejvs.2006.04.021
  20. Phillips M, Jones G, van Rij A, Zhang M. Micro-venous valves in the superficial veins of the human lower limb. Clinical Anatomy. 2004;17(1):55-60. https://doi.org/10.1002/ca.10141
  21. Rabe E, Puskas A, Scuderi A, Fernandez Quesada F, VCP Coordinators. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105-115.
  22. Tsukanov YT, Nikolaichuk AI. Orthostatic-loading-induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein. Int Angiol. 2017;36(2):189-196.
  23. Bates D, Hillman N, Pocock T, Neal C. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat. 2002;200(5):523-534. https://doi.org/10.1046/j.1469-7580.2002.00047_19.x
  24. Hosoi Y, Zukowski A, Kakkos S, Nicolaides A. Ambulatory venous pressure measurements: New parameters derived from a mathematic hemodynamic model. J Vasc Surg. 2002;36(1):137-142. https://doi.org/10.1067/mva.2002.124622
  25. Virgini-Magalhães C, Porto C, Fernandes F, Dorigo D, Bottino D, Bouskela E. Use of microcirculatory parameters to evaluate chronic venous insufficiency. J Vasc Surg. 2006;43(5):1037-1044. https://doi.org/10.1016/j.jvs.2005.12.065
  26. Pocock E, Alsaigh T, Mazor R, Schmid-Schönbein G. Cellular and molecular basis of Venous insufficiency. Vascular Cell. 2014;6(1). https://doi.org/10.1186/s13221-014-0024-5
  27. Stanley A, Park H, Phillips T, Russakovsky V, Menzoian J. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg. 1997;26(6):994-1001. https://doi.org/10.1016/s0741-5214(97)70012-0
  28. Yasim A, Kilinç M, Aral M, Oksuz H, Kabalci M, Eroglu E, Imrek S. Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins. Phlebology: The Journal of Venous Disease. 2008;23(1):15-20. https://doi.org/10.1258/phleb.2007.007014
  29. Kim I, Moon S, Hoon Kim S, Jin Kim H, Soon Koh Y, Young Koh G. Vascular Endothelial Growth Factor Expression of Intercellular Adhesion Molecule 1 (ICAM-1), Vascular Cell Adhesion Molecule 1 (VCAM-1), and e-selectin through nuclear factor-κB activation in endothelial cells. Journal of Biological Chemistry. 2000;276(10):7614-7620. https://doi.org/10.1074/jbc.m009705200
  30. Perrin M, Ramelet A. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. European Journal of Vascular and Endovascular Surgery. 2011;41(1):117-125. https://doi.org/10.1016/j.ejvs.2010.09.025
  31. Bergan J, Schmid-Schönbein G, Smith P, Nicolaides A, Boisseau M, Eklof B. Chronic venous disease. New England Journal of Medicine. 2006;355(5):488-498. https://doi.org/10.1056/nejmra055289
  32. Serralheiro P, Soares A, Costa Almeida C, Verde I. TGF-β1 in vascular wall pathology: unraveling chronic venous insufficiency pathophysiology. Int J Mol Sci. 2017;18(12):2534. https://doi.org/10.3390/ijms18122534
  33. Raffetto J, Khalil R. Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol. 2008;6(3):158-172. https://doi.org/10.2174/157016108784911957
  34. Nicolaides A, Kakkos S, Eklof B, Perrin M, Nelzen O, Neglen P, Partsch H, Rybak Z. Management of chronic venous disorders of the lower limbs — guidelines according to scientific evidence. Int Angiol. 2014;33(2):87-208.
  35. Vital A, Carles D, Serise J, Boisseau M. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. International Journal of Angiology. 2010;19(02):e73-e77. https://doi.org/10.1055/s-0031-1278374
  36. Danziger N. Physiopathologie de la douleur au cours de la maladie veineuse. J Mal Vasc. 2007;32(1):1-7.
  37. Savel’eva MI, Sychev DA. Potential of the transdermal drug delivery systems for the topical treatment of chronic venous diseases. Flebologiya. 2018;12(1):40-49. (In Russ.)
  38. Sirtori C. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res. 2001;44(3):183-193. https://doi.org/10.1006/phrs.2001.0847
  39. Nieman D, Haig J, Fairchild K, De Guia E, Dizon G, Register U. Reducing-diet and exercise-training effects on serum lipids and lipoproteins in mildly obese women. Am J Clin Nutr. 1990;52(4):640-645. https://doi.org/10.1093/ajcn/52.4.640
  40. Ibegbuna V, Nicolaides A, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology. 1997;48(1):45-49. https://doi.org/10.1177/000331979704800108
  41. Frick R, Frick R. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology. 2000;51(3):197-205. https://doi.org/10.1177/000331970005100303
  42. Boudet C, Peyrin L. Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat. Arch Int Pharmacodyn Ther. 1986;283(2):312-320.
  43. Martinez-Zapata M, Vernooij R, Uriona Tuma S, et al. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. 2016. https://doi.org/10.1002/14651858.cd003229.pub3
  44. Pascarella L, Lulic D, Penn A, et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. J Vasc Surg. 2008; 47(1):243. https://doi.org/10.1016/j.jvs.2007.11.018
  45. Pietrzycka A, Kózka M, Urbanek T, Stpniewski M, Kucharzewski M. Effect of micronized purified flavonoid fraction therapy on endothelin-1 and TNF-α levels in relation to antioxidant enzyme balance in the peripheral blood of women with varicose veins. Curr Vasc Pharmacol. 2015;13(6):801-808. https://doi.org/10.2174/1570161113666150827124714
  46. Paysant J, Sansilvestri-Morel P, Bouskela E, Verbeuren TJ. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Int Angiol. 2008;27(1):81-85.
  47. Amato C. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized Diosmin. Angiology. 1994;45(6_part_2):531-536. https://doi.org/10.1177/000331979404500606
  48. Garner R, Garner J, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J Pharm Sci. 2002;91(1):32. https://doi.org/10.1002/jps.1168.abs
  49. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction. Phlebolymphology. 2016;23(2):82-91.
  50. Diosmin. Monograph. Altern Med Rev. 2004;9(3):308-311.
  51. Fermoso J, Legido A, Del Pino J, Valiente R. Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs. Current Therapeutic Research. 1992;52(1):124-134. https://doi.org/10.1016/s0011-393x(05)80444-8
  52. Kakkos SK, Allaert FA. Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort, on improving individual venous symptoms and edema: a systematic review and metaanalysis of randomized double-blind placebo-controlled trials. Int Angiol. 2017;36(2):93-106.
  53. Kakkos S, Bouskela E, Jawien A, Nicolaides A. New data on chronic venous disease: a new place for Cyclo 3. Fort Int Angiol. 2018;37(1):85-92.
  54. MacLennan W, Wilson J, Rattenhuber V, Dikland W, Vanderdonckt J, Moriau M. Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: its efficacy and tolerability. Gerontology. 1994;40(1):45-52. https://doi.org/10.1159/000213574
  55. Allaert FA. Metaanalysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31(4):310-315.
  56. de Souza M, Cyrino F, Mayall M, Virgini-Magalhães CE, Sicuro FL, Carvalho JJD, Verbeuren TJ, Bouskela E. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology: The Journal of Venous Disease. 2014;31(1):50-56. https://doi.org/10.1177/0268355514564414
  57. Ramelet AA, Boisseau MR, Allegra C, Nicolaides A, Jaeger K, Carpentier P, Cappelli R, Forconi S. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc. 2005;33(4):309-319.
  58. Coleridge-Smith P, Lok C, Ramelet A. Venous leg ulcer: a metaanalysis of adjunctive therapy with micronized purified flavonoid fraction. European Journal of Vascular and Endovascular Surgery. 2005;30(2):198-208. https://doi.org/10.1016/j.ejvs.2005.04.017
  59. Guilhou J, Dereure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, Van Landuyt H, Gillet-Terver M, Guillot B, Levesque H, Mignot J, Pillion G, Février B, Dubeaux D.. Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients. Angiology. 1997;48(1):77-85. https://doi.org/10.1177/000331979704800113
  60. Roztocil K, Stvrtinová V, Strejcek J. Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol. 2003;22(1):24-31.
  61. Scallon C, Bell-Syer S, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database of Systematic Reviews. 2013. https://doi.org/10.1002/14651858.cd006477.pub2
  62. Pedersen FM, Hamberg O, Sorensen MD, Neland K. Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskr Laeger. 1992;154(38):2561-2563.
  63. Cazaubon M, Bailly C, Ducros E, Lancrenon S. Acceptability, efficacy and safety of two pharmaceutical forms of diosmin 600 mg in patients with chronic venous disease: a randomised comparative multicenter study. Angiology. 2011;12:1-8.
  64. Balmer A, Limoni C. Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients. Vasa. 1980;9(1):76-82.
  65. Bogachev VYu, Golovanova OV, Kuznetsov AN, Shekoian AO. On advisability of perioperative phleboprotection in endovascular treatment of lower in varicose disease: first initial results of the decision study. Angiol Sosud Khir. 2012;18(2):90-95. (In Russ.)
  66. Pokrovsky AV, Sapelkin SV, Saveljev VS, Kirienko AI, Bogachev VYu, Zolotukhin IA. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial Defance. Phlebolymphology. 2008;.15(2):45-51.
  67. Lacroix I, Beau A, Hurault-Delarue C, Bouilhac C(3), Petiot D(4), Vayssière C(5), Vidal S, Montastruc JL, Damase-Michel C. First epidemiological data for venotonics in pregnancy from the EFEMERIS database. Phlebology: The Journal of Venous Disease. 2015;31(5):344-348. https://doi.org/10.1177/0268355515589679
  68. Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. Phlebology: The Journal of Venous Disease. 1994;9(2):67-70. https://doi.org/10.1177/026835559400900206
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.